Clinical Trials Browser

Has results × Breast Neoplasms × Erlotinib Hydrochloride × Clear all

NCT00597597 2023-05-17

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Phase 2 Terminated

11 enrolled 12 charts

Breast Neoplasms

NCT00570258 2021-03-30

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Phase 2 Terminated

27 enrolled 7 charts

Breast Neoplasms

NCT00033514 2020-10-08

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Phase 1/2 Completed

27 enrolled 12 charts

Breast Neoplasms

NCT00503841 2019-04-30

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Phase NA Terminated

44 enrolled 3 charts

Breast Neoplasms

NCT00733408 2018-12-04

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Phase 2 Completed

59 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00834678 2018-04-17

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Phase 1/2 Completed

11 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00054132 2017-07-24

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Phase 2 Completed

38 enrolled 10 charts

Breast Neoplasms

NCT00054275 2016-02-17

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Phase 2 Completed

39 enrolled 7 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00633750 2012-09-05

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

50 enrolled 9 charts

Breast Neoplasms

NCT00611715 2012-08-09

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

Phase 2 Terminated

48 enrolled 11 charts

Breast Neoplasms

NCT00739063 2012-03-15

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Phase 2 Terminated

11 enrolled 5 charts

Breast Neoplasms